Biomarkers Assessing Endothelial Dysfunction in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common degenerative disorder in the elderly in developed countries. Currently, growing evidence is pointing at endothelial dysfunction as a key player in the cognitive decline course of AD. As a main component of the blood–brain barrier (BBB), the dysfunction of endothelial cells driven by vascular risk factors associated with AD allows the passage of toxic substances to the cerebral parenchyma, producing chronic hypoperfusion that eventually causes an inflammatory and neurotoxic response. In this process, the levels of several biomarkers are disrupted, such as an increase in adhesion molecules that allow the passage of leukocytes to the cerebral parenchyma, increasing the permeability of the BBB; moreover, other vascular players, including endothelin-1, also mediate artery inflammation. As a consequence of the disruption of the BBB, a progressive neuroinflammatory response is produced that, added to the astrogliosis, eventually triggers neuronal degeneration (possibly responsible for cognitive deterioration). Recently, new molecules have been proposed as early biomarkers for endothelial dysfunction that can constitute new therapeutic targets as well as early diagnostic and prognostic markers for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102 · cited 1×
“It is also important to mention that BBB leakage in the hippocampus also occurs in aging in an age-dependent manner [48].”
BackgroundOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
VEGF enhances angiogenesis and promotes blood–brain barrier leakage in the ischemic brain
Zhang, Z. G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C., Bruggen, N. V., & Chopp, M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9369 · Cited by 1,296 · cited 1×
“However, under ischemic conditions, VEGF also has harmful effects on the central nervous system by promoting BBB leakage in the brain [116] (Figure 2).”
BackgroundNeutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., Turano, E., Rossi, B., Angiari, S., Dusi, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3913 · Cited by 865
VEGF links hippocampal activity with neurogenesis, learning and memory
Cao, L., Jiao, X., Zuzga, D. S., Liu, Y., Fong, D. M., Young, D., & During, M. J. (2004) · Nature Genetics · doi:10.1038/ng1395 · Cited by 850 · cited 2×
“VEGF is a growth factor primarily involved in vasculogenesis and angiogenesis, and it is essential for proper vascular homeostasis [112,113]; moreover, VEGF is involved in adult hippocampal neurogenesis and hippocampal-dependent memory by increasing synaptic strength [114,115].”
BackgroundResultLuissint, A.-C., Artus, C., Glacial, F., Ganeshamoorthy, K., & Couraud, P.-O. (2012) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-9-23 · Cited by 654 · cited 1×
“Tight junctions (TJ) are fundamental elements for the correct maintenance of the BBB that connect endothelial cells with each other [31].”
BackgroundHalliday, M. R., Rege, S. V., Ma, Q., Zhao, Z., Miller, C. A., Winkler, E. A., & Zlokovic, B. V. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.44 · Cited by 649
Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H. (2016) · Radiology · doi:10.1148/radiol.2016152244 · Cited by 601
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Microvascular injury and blood–brain barrier leakage in Alzheimer's disease
Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., Vitek, M. P., Hovanesian, V., & Stopa, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.016 · Cited by 487
Endothelial microparticles in diseases
Chironi, G. N., Boulanger, C. M., Simon, A., Dignat-George, F., Freyssinet, J.-M., & Tedgui, A. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0710-9 · Cited by 420
Ryu, J. K., & McLarnon, J. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00434.x · Cited by 406
CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018) · Neurology · doi:10.1212/wnl.0000000000006082 · Cited by 359
Fiala, M., Liu, Q. N., Sayre, J., Pop, V., Brahmandam, V., Graves, M. C., & Vinters, H. V. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00994.x · Cited by 307
Carrano, A., Hoozemans, J. J. M., van der Vies, S. M., Rozemuller, A. J. M., van Horssen, J., & de Vries, H. E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3895 · Cited by 293
Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence
Vaughan, D. E., Rai, R., Khan, S. S., Eren, M., & Ghosh, A. K. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309451 · Cited by 258
Janelidze, S., Hertze, J., Nägga, K., Nilsson, K., Nilsson, C., Wennström, M., van Westen, D., Blennow, K., Zetterberg, H., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.017 · Cited by 237 · cited 3×
“Several studies showed that AD patients have elevated ratios of both CSF/plasma [73,74] and CSF/serum [75–77] albumin compared to controls.”
BackgroundFestoff, B. W., Sajja, R. K., van Dreden, P., & Cucullo, L. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0670-z · Cited by 214
Miners, J. S., Schulz, I., & Love, S. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17690761 · Cited by 208 · cited 3×
“For example, a decreased myelin-associated glycoprotein/proteolipid protein-1 ratio, which indicates hypoperfusion, was detected in AD brains [21,36].”
BackgroundNeurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging
van de Haar, H. J., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Wong, S. M., Hofman, P. A. M., Burgmans, S., Verhey, F. R. J., & Backes, W. H. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.006 · Cited by 207
Yamazaki, Y., Shinohara, M., Shinohara, M., Yamazaki, A., Murray, M. E., Liesinger, A. M., Heckman, M. G., Lesser, E. R., Parisi, J. E., Petersen, R. C., et al. (2019) · Brain · doi:10.1093/brain/awz011 · Cited by 202
Deo, A. K., Borson, S., Link, J. M., Domino, K., Eary, J. F., Ke, B., Richards, T. L., Mankoff, D. A., Minoshima, S., O’Sullivan, F., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.130161 · Cited by 193
Bjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180 · cited 3×
“[98] - CSF samples from AD patients displayed increased levels of MMP-10, which were correlated with T-tau concentration.”
BackgroundWhite matter hyperintensity topography in Alzheimer's disease and links to cognition
Garnier‐Crussard, A., Bougacha, S., Wirth, M., Dautricourt, S., Sherif, S., Landeau, B., Gonneaud, J., De Flores, R., de la Sayette, V., Vivien, D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12410 · Cited by 170
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152
Incidence of cerebral microbleeds in preclinical Alzheimer disease
Yates, P. A., Desmond, P. M., Phal, P. M., Steward, C., Szoeke, C., Salvado, O., Ellis, K. A., Martins, R. N., Masters, C. L., Ames, D., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000285 · Cited by 150 · cited 1×
“3–41%, while the prevalence varies between 40–48% in AD subjects [50,51].”
BackgroundThe vascular factor in Alzheimer's disease: A study in Golgi technique and electron microscopy
Baloyannis, S. J., & Baloyannis, I. S. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.07.010 · Cited by 150 · cited 2×
“Accordingly, decreased pericyte marker platelet-derived growth factor receptor-β (PDGFRβ) and marked degeneration of pericytes were observed [13,15,19].”
BackgroundShedding of soluble platelet-derived growth factor receptor-β from human brain pericytes
Sagare, A. P., Sweeney, M. D., Makshanoff, J., & Zlokovic, B. V. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.09.025 · Cited by 142
Pericapillary Haem-Rich Deposits: Evidence for Microhaemorrhages in Aging Human Cerebral Cortex
Cullen, K. M., Kócsi, Z., & Stone, J. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600155 · Cited by 137 · cited 9×
“Recently, a study assessed the use of new MRI-based technology to study the BBB permeability in MCI patients without contrast agents, by analyzing the leakage of small molecules, such as water [47].”
BackgroundInfluentialExpression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer’s disease
Frohman, E. M., Frohman, T. C., Gupta, S., de Fougerolles, A., & van den Noort, S. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90202-i · Cited by 120
Endothelin-1 is Elevated in Alzheimer's Disease and Upregulated by Amyloid-β
Palmer, J. C., Barker, R., Kehoe, P. G., & Love, S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111760 · Cited by 110 · cited 1×
“Controversially, elevated levels of ET-1 were also detected in AD brain samples [84].”
BackgroundKallmann, B. A. (2000) · Brain · doi:10.1093/brain/123.4.687 · Cited by 106
High Prevalence of Cerebral Microbleeds at 7Tesla MRI in Patients with Early Alzheimer's Disease
Brundel, M., Heringa, S. M., de Bresser, J., Koek, H. L., Zwanenburg, J. J. M., Kappelle, L. J., Luijten, P. R., & Biessels, G. J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120364 · Cited by 97
Reduced circulating angiogenic cells in Alzheimer disease
Lee, S.-T., Chu, K., Jung, K.-H., Park, H.-K., Kim, D.-H., Bahn, J.-J., Kim, J.-H., Oh, M.-J., Lee, S. K., Kim, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a711f4 · Cited by 61
Decreased serum angiogenin level in Alzheimer's disease
Kim, Y. N., & Kim, D. H. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.010 · Cited by 55
Uetani, H., Hirai, T., Hashimoto, M., Ikeda, M., Kitajima, M., Sakamoto, F., Utsunomiya, D., Oda, S., Sugiyama, S., Matsubara, J., et al. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3332 · Cited by 48 · cited 1×
“3–41%, while the prevalence varies between 40–48% in AD subjects [50,51].”
BackgroundSerum sEPCR Levels Are Elevated in Patients With Alzheimer’s Disease
Zhu, Y., Chen, Z., Chen, X., & Hu, S. (2015) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317514567124 · Cited by 9
Cited by
Yue, Q., Leng, X., Xie, N., Zhang, Z., Yang, D., & Hoi, M. P. M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70079 · Cited by 48
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
“Vascular alterations in brain samples from AD patients show neurotoxic substances, such as fibrinogen, in the parenchyma due to their ability to pass the BBB [142,143].”
BackgroundTanaka, M., Battaglia, S., & Liloia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13051045 · Cited by 24
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
Metadata
- Authors
- Custodia, A., Aramburu-Núñez, M., Rodríguez-Arrizabalaga, M., Pías-Peleteiro, J. M., Vázquez-Vázquez, L., Camino-Castiñeiras, J., Aldrey, J. M., Castillo, J., Ouro, A., Sobrino, T., & Romaus-Sanjurjo, D.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-03-22
- Volume
- 12
- Issue
- 6
- Pages
- 962
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4353069309
- Cited by
- 44
- References
- 37
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.